Zobrazeno 1 - 10
of 41
pro vyhledávání: '"John Gutheil"'
Autor:
Robert McRae, Ivor Royston, Anusha Vallurupalli, P. Daniels, Sebastian Obrzut, Douglas V. Faller, T. Melink, J. Woody, Brad M. Haverkos, Hao Shen, Rosemary Rochford, Elizabeth Brem, Corey Casper, Pierluigi Porcu, Onder Alpdogan, Stefan K. Barta, Locke J. Bryan, C. Kearns, Jonathan E. Brammer, A. Schriefer, John Gutheil, Marshelle Smith Warren, D. Burner, Tatyana Feldman, Robert A. Baiocchi
Publikováno v:
Hematological Oncology. 37:335-337
Autor:
Donald L. Lamm, Vignesh T. Packiam, Karim Chamie, A. Karim Kader, Arthur Kuan, John Gutheil, Kirsten Dorr, Gary D. Steinberg, Ronald L. Davis, Daniel A. Barocas
Publikováno v:
Journal of Urology. 201
INTRODUCTION AND OBJECTIVES:CG0070 is a selective oncolytic adenovirus that exploits retinoblastoma (Rb) pathway defects. We have previously shown promising interim results for this agent. We prese...
Autor:
Tatyana Feldman, Robert McRae, Ivor Royston, Elizabeth Brem, Douglas V. Faller, Marcelo Capra, Anusha Vallurupalli, Jonathan E. Brammer, Sebastian Obrzut, Afton Katkov, Ana Fernandes Schriefer, Locke J. Bryan, Onder Alpdogan, John Gutheil, Juliana Pereira, Brad M. Haverkos, Anil Tulpule, Stefan K. Barta, Pierluigi Porcu, Richard Trauger
Publikováno v:
Blood. 134:465-465
Background: EBV-positive (EBV+) cells are detectable in a variable but significant fraction of lymphomas of all lineages and histologic type by in situ hybridization for EBV-encoded RNA (EBER-ISH). EBV positivity generally confers a worse prognosis i
Autor:
Donald L. Lamm, John Gutheil, Gary D. Steinberg, Vignesh T. Packiam, A. Karim Kader, Ronald L. Davis, Daniel A. Barocas, Karim Chamie, Arthur Kuan
Publikováno v:
Journal of Urology. 199
Autor:
William R. Wilson, Naval Daver, Peter F. Thall, Hagop M. Kantarjian, Tapan M. Kadia, Naveen Pemmaraju, Jennie Feliu, Andrew Coveler, John Gutheil, Sergej Konoplev, Caimiao Wei, Carlos E. Bueso-Ramos, Stefan Faderl, Hongbo Lu, Cecilia Arana Yi, Hoang Q. Nguyen, Juliana Benito, Farhad Ravandi, Jorge E. Cortes, Deborah A. Thomas, Yongchuan Gu, Michael Andreeff, Teresa J. Melink, Marina Konopleva, Elihu H. Estey, Elias Jabbour, Steven M. Kornblau, Gautam Borthakur
Publikováno v:
Haematologica. 100:927-934
We previously demonstrated vast expansion of hypoxic areas in the leukemic microenvironment and provided a rationale for using hypoxia-activated prodrugs. PR104 is a phosphate ester that is rapidly hydrolyzed in vivo to the corresponding alcohol PR-1
Autor:
Rosemary Rochford, Douglas V. Faller, Sebastian Obrzut, Stefan K. Barta, John Gutheil, Ivor Royston, Robert McRae, Bradley M. Haverkos, Tatyana Feldman, Anusha Vallurupalli, Locke J. Bryan, Preston Daniels, Jonathan E. Brammer, Marshelle Smith Warren, Corey Casper, Onder Alpdogan, Pierluigi Porcu, Elizabeth Brem, Robert A. Baiocchi, Hao Shen
Publikováno v:
Journal of Clinical Oncology. 37:7551-7551
7551 Background: Nanatinostat (N; VRx-3996) is a Class I-selective oral hydroxamate histone deacetylase (HDAC) inhibitor active against HDAC 1-3, but not HDAC 6. N induces expression of EBV thymidine kinase (TK, BXLF1) and protein kinase (PK, BGLF4)
Autor:
Erkut Borazanci, Eileen A. O'Reilly, Christine M. Kearns, Marvin Peterson, Joseph A. O'Donoghue, Jack Ostrowski, Wolfgang A. Weber, John Gutheil, Jason S. Lewis, Christian Lohrmann, Kirsten Dorr, Terri Melink, Paul W. Maffuid, Rebecca Teng, Hayley Estrella
Publikováno v:
Cancer Research. 78:CT140-CT140
Objectives and Background: The study is designed to establish a recommended phase 2 dose (RP2D) for the treatment of CA19-9+ malignancies with MVT-1075/MVT-5873 radioimmunotherapy (RIT). 177Lu-CHX-A″-DTPA-HuMab-5B1 (MVT-1075) consists of the fully-
Autor:
Kenneth H. Yu, Hayley Estrella, Teresa J. Melink, Paul W. Maffuid, David Kamins, Kirsten Dorr, Todd M. Bauer, John Gutheil, Judy Sing-Zan Wang, Eileen M. O'Reilly, Erkut Borazanci, Anna M. Varghese
Publikováno v:
Journal of Clinical Oncology. 36:e16235-e16235
e16235Background: MVT-5873, a fully human IgG1 mAb, targets sialyl Lewis A (sLea), an epitope on CA19-9. CA19-9 is expressed in PDAC and other GI and lung cancers, plays a role in tumor adhesion an...
Autor:
Maeve A. Lowery, Hayley Estrella, Anna M. Varghese, Mariella Hoskins, Paul W. Maffuid, Johanna C. Bendell, Kenneth H. Yu, Stephanie Bussen, Eileen M. O'Reilly, Christine M. Kearns, Todd M. Bauer, H. Toni Jun, Kimberly M. Fowler, Erkut Borazanci, Judy Wang, Teresa J. Melink, John Gutheil
Publikováno v:
Molecular Cancer Therapeutics. 17:LB-B25
IntroductionMVT-5873, a fully human IgG1 monoclonal antibody (mAb), targets sialyl Lewis A (sLea), an epitope on CA19-9. CA19-9 is expressed in pancreatic (PDAC) and other GI cancers, plays a role in tumor adhesion and metastasis, and is a marker of
Autor:
Mark D. Pegram, Danny Rischin, John Gutheil, William A. Denny, Michael B. Jameson, Adam V. Patterson, William R. Wilson
Publikováno v:
Cancer Chemotherapy and Pharmacology. 65:791-801
PR-104 is a "pre-prodrug" designed to be activated to a dinitrobenzamide nitrogen mustard cytotoxin by nitroreduction in hypoxic regions of tumors. This study was conducted to establish the maximum tolerated dose (MTD), dose-limiting toxicity (DLT),